title: Binding characteristics and vascular effects of various angiotensin II antagonists.
abstract: Subtypes of angiotensin II (Ang II) receptors have been recently identified using specific ligands (see Whitebread et al. Biochem Biophys Res Comm 1989; 163:284-291). The present study compares the binding characteristics of different structural classes of Ang II receptor ligands in rat aortic smooth muscle cells (Ang IIB subtype) and in human uterus (Ang IIA subtype) and their effects on the constrictor response to Ang II in isolated rabbit aortic rings. Saralasin and [Sar1 Ile8]-Ang II displayed similar affinity for the two subtypes. In contrast, CGP 42112A bound with high affinity to the uterus (Ki 0.24 nM), but showed a low affinity for the aortic receptor (Ki 1,760 nM). Compound 89 displayed affinity for the aortic receptor only (Ki 26 nM) whereas Ex 169 recognized specifically the uterus receptor (Ki 310 nM). In rabbit aortic rings, saralasin, [Sar1 Ile8]Ang II, CGP42112A and compound 89 inhibited Ang II-induced contractions at concentrations similar to those required to bind to the Ang IIB receptor subtype. IC50s were 3, 0.7, 1,850, and 23 nM respectively. Ex 169 was ineffective in concentrations up to 100 microM. There was a highly significant correlation between inhibition of Ang II-induced contraction in aortic rings and binding to smooth muscle cells. This correlation does not exist with human uterus. Our results indicate that the Ang IIB receptor subtype is responsible for vascular contractions. Antagonists of this vascular receptor subtype are potential antihypertensive agents.
authors.affiliation: Cardiovascular, Department, Ciba-Geigy Ltd., Basel, Switzerland.
authors.forename: L
authors.initials: L
authors.lastname: Criscione
authors.forename: H
authors.initials: H
authors.lastname: Thomann
authors.forename: S
authors.initials: S
authors.lastname: Whitebread
authors.forename: M
authors.initials: M
authors.lastname: de Gasparo
authors.forename: P
authors.initials: P
authors.lastname: Bühlmayer
authors.forename: P
authors.initials: P
authors.lastname: Herold
authors.forename: F
authors.initials: F
authors.lastname: Ostermayer
authors.forename: B
authors.initials: B
authors.lastname: Kamber
mesh_terms: D000804:Angiotensin II / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000809:Angiotensins; D000818:Animals; D001011:Aorta; D001713:Biphenyl Compounds / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D008024:Ligands; D019808:Losartan; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009842:Oligopeptides / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011945:Receptors, Angiotensin / Q000187:drug effects*; D012504:Saralasin / Q000494:pharmacology; D014599:Uterus
chemical_list: D057911:Angiotensin Receptor Antagonists; D000809:Angiotensins; D001713:Biphenyl Compounds; D007093:Imidazoles; D008024:Ligands; D009842:Oligopeptides; D011945:Receptors, Angiotensin; D000804:Angiotensin II; C060894:CGP 42112A; C067583:Ex 169; C009210:sarleucin; D012504:Saralasin; D019808:Losartan